Diabetes medications help to fight gout
Sodium glucose transporter protein 2 inhibitor (SGLT2) lowers blood glucose levels and is considered a standard therapeutic intervention to treat the progression of diabetic kidney disease and cardiovascular complications in patients with type 2 diabetes. Scientists say that patients with type 2 diabetes who receive sodium glucose co-transporter type 2 (SGLT2) inhibitors have the lowest risk of gout compared to those who receive dipeptidyl peptidase-4 (DPP4) inhibitors.
Since hyperukinemia is considered an important risk factor for gout, researchers from National Zhong Xin University believe that SGLT2 inhibitors might affect the risk of gout. They also found that various SGLT2 inhibitors promoted the release of more uric acid and reduced the level of urate in the blood down to 0.3-0.9 mg/dL. In a study analyzing data of 231,208 people with type 2 diabetes, it was found that SGLT2 inhibitors could reduce the incidence of gout by 11% in these patients.